Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
DATA PRESENTED FROM COLLABORATION OF PHARMAXIS AND UNIVERSITY OF ROCHESTER MEDICAL CENTER AT US SCIENTIFIC MEETING
COMBINATION OF PXS-5505 AND STANDARD OF CARE DEMONSTRATES A NOVEL THERAPEUTIC STRATEGY FOR LIVER CANCER
SYDNEY, Aug. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first...
Read more: Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model




